Intermountain Health's AI Initiative and Regeneron's $100M Bet: Advancements in Health IT and Biomedicine

04/26/24 • 4 min

"AI in Life Sciences" dives into the world where technology and biology intersect, providing expert insight and analysis on the latest trends, breakthroughs, and controversies. In this episode, we explore a potential bird flu threat in Midwestern milk, the innovative use of AI in tackling workforce shortages in healthcare, and impressive revenue growth in AstraZeneca, thanks in part to their cancer drugs. We also discuss Regeneron Pharmaceuticals’ $100M wager on Mammoth’s CRISPR technology, the crucial role of AI understanding for health IT leaders, and how AI is revolutionizing drug discovery at AION Labs. Finally, we delve into Bristol Myers Squibb’s major restructuring and its implications for employees and the company's future growth. Stay tuned for these stories and more on "AI in Life Sciences".

Previous Episode

"From Novartis' New Chair to AI Advancements: Key Insights in Pharma and Tech"

AI in Life Sciences is a podcast that keeps a finger on the pulse of technological advancement within the healthcare and pharmaceutical fields. In this episode, we'll take a deep dive into Novartis AG's recent nomination of former Bristol Myers CEO Giovanni Caforio as incoming chair, examining what this could mean for the company's future amidst the global competition. We'll then switch gears to discuss the ongoing reorganization of AI-driven drug developer, BenevolentAI, and how shifting priorities are impacting its workforce. The episode will also cover Ultrahuman's anticipated expansion into the US market through the establishment of a manufacturing center in Indiana, a move benefiting domestic production and job creation. Finally, we'll review Basware's new AP Protect tool, designed to detect errors and fraudulent activities in finance teams using advanced AI algorithms. Join us for thought-provoking insights into how AI continues to revolutionize the life sciences sector.

Next Episode

Securing the Cyberworld: Seven AI's Funding Success and Mission

This episode of 'AI in Life Sciences' presents exciting updates from the world of artificial intelligence and its game-changing applications in the Life Sciences sector. Pioneering the breakthroughs, in our first news item, Seven AI has garnered an impressive $36 million in initial funding. This considerable investment will bolster the tech company's ambition to equip businesses with AI-powered cybersecurity. As cyber threats grow more sophisticated, Seven AI's adaptive software is a remarkable step towards empowering digital defenses. Notably, Greylock took the lead in this round, boosting the cybersecurity company's value to over $100 million.